Viking Therapeutics VKTX
NASDAQ VKTX
$36.75 -4.90 (-11.76%)
At close: Sep 24, 2026 · 4:00 PM EDT

Viking Therapeutics (VKTX) Income from Continuing Operations (2014 - 2026)

Viking Therapeutics' (VKTX) quarterly Income from Continuing Operations came in at -$128.1 million in Q2 2026, down 95.38% year-over-year from -$2.8 billion in Q2 2025, and up 19.12% quarter-over-quarter from -$158.3 million in Q1 2026.

Analysis

Viking Therapeutics (VKTX) Income from Continuing Operations (2014 - 2026) Analysis & Trends

Viking Therapeutics has disclosed Income from Continuing Operations across 13 years of filings, most recently posting -$128.1 million for Q2 2026.

  • In Q2 2026, Income from Continuing Operations fell 95.38% year-over-year to -$128.1 million; the TTM figure through Jun 2026 stood at -$534.9 million (down 211.76% YoY), while the FY2025 annual figure was -$359.6 million, down 227.0% from the prior year.
  • Income from Continuing Operations came in at -$128.1 million for Q2 2026 at Viking Therapeutics, up from -$158.3 million in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of -$15.7 million in Q3 2022 to a low of -$158.3 million in Q1 2026.
  • Average Income from Continuing Operations over 5 years is -$50.6 million, with a median of -$24.8 million recorded in 2023.
  • Year-over-year, Income from Continuing Operations fell 10.44% in 2023 and slumped 345.56% in 2025.
  • Over 5 years, Income from Continuing Operations stood at -$19.6 million in 2022, then fell by 25.72% to -$24.6 million in 2023, then tumbled by 44.0% to -$35.4 million in 2024, then sank by 345.56% to -$157.7 million in 2025, then grew by 18.8% to -$128.1 million in 2026.
  • Per Business Quant data, the three most recent Income from Continuing Operations figures were -$128.1 million in Q2 2026, -$158.3 million in Q1 2026, and -$157.7 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Johnson & Johnson 649.01 Bn 628.25 Bn 17.26 Bn 5.53 Bn
2 AbbVie 468.55 Bn 462.03 Bn 12.70 Bn 3.62 Bn
3 Merck 365.49 Bn 358.40 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 272.39 Bn 265.10 Bn 11.24 Bn 5.28 Bn
5 Astrazeneca 253.18 Bn 247.96 Bn 12.86 Bn 3.09 Bn
6 Amgen 219.53 Bn 205.54 Bn 7.24 Bn 2.38 Bn
7 Gilead Sciences 187.85 Bn 184.59 Bn 6.22 Bn -10.50 Bn
8 Pfizer 160.56 Bn 149.16 Bn 10.94 Bn -246.00 Mn
9 Vertex Pharmaceuticals 130.81 Bn 122.96 Bn 2.84 Bn 1.10 Bn
10 Viking Therapeutics 4.86 Bn 4.86 Bn - -128.05 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -128.05 Mn
Mar 31, 2026 -158.33 Mn
Dec 31, 2025 -157.70 Mn
Sep 30, 2025 -90.79 Mn
Jun 30, 2025 -65.54 Mn
Mar 31, 2025 -45.61 Mn
Dec 31, 2024 -35.39 Mn
Sep 30, 2024 -25.03 Mn
Jun 30, 2024 -22.23 Mn
Mar 31, 2024 -27.33 Mn
Dec 31, 2023 -24.58 Mn
Sep 30, 2023 -22.53 Mn
Jun 30, 2023 -19.19 Mn
Mar 31, 2023 -19.50 Mn
Dec 31, 2022 -19.55 Mn
Sep 30, 2022 -15.75 Mn
Jun 30, 2022 -17.38 Mn
Mar 31, 2022 -17.14 Mn
Dec 31, 2021 -12.35 Mn
Sep 30, 2021 -13.28 Mn
API Access

Viking Therapeutics Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=VKTX&period=max&api_key=YOUR_API_KEY